Churchill Capital Corp XI - Class A Ordinary Shares (CCXI)

Agility Robotics, Inc. (“Agility” or the “Company”) creator of the general-purpose humanoid robot Digit, and Churchill Capital Corp XI (NASDAQ: CCXI) (“CCXI” or “Churchill XI”), a special purpose acquisition company, today announced the confidential submission of a draft registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC").

SpaceX shares fell 8% after Nasdaq 100 inclusion as Grok's market share slipped, while Tesla dropped 7% despite a delivery beat, reflecting fading AI-driven valuation premiums.

The CCXI-Agility Robotics SPAC merger will create the first U.S.-listed pure-play humanoid equity, valued at $2.5B, with clients including Amazon and a NVIDIA partnership.

Agility Robotics, Inc. (“Agility” or the “Company”), a leading humanoid robotics and physical AI company, and Churchill Capital Corp XI (NASDAQ: CCXI) (“Churchill”), a publicly traded special purpose acquisition company, today announced they have entered into a definitive business combination agreement (the “Transaction”). Upon closing of the Transaction, the combined company is expected to operate as Agility and be listed on a major North American exchange under the ticker symbol “AGLT.”

Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. 

-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR --

The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far.

-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model --

We have used the August return data from finviz.com to come up with the five best and worst performing mid-cap stocks in August 2022.

The biotech run off a June bottom is great — until you realize you could've netted more.

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of ChemoCentryx, Inc. (“ChemoCentryx”) (NASDAQ: CCXI) breached their fiduciary duties to ChemoCentryx and its shareholders. If you are a ChemoCentryx shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or jpettigrew@scott-scott.com.

Robust Dow stocks offer attractive deals for patient investors amidst an unstable economic environment

The summer rally is over it’s a holiday weekend with low trading volume and bad news is pervasive. A decent jobs report on Friday brought in buyers in early hours until Russia intervened with a Nord Stream suspension of natural gas to Germany.

According to data from Benzinga Pro, during Q2, ChemoCentryx's (NASDAQ:CCXI) reported sales totaled $11.76 million. Despite a 18.02% increase in earnings, the company posted a loss of $31.65 million.

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of ChemoCentryx, Inc. (“ChemoCentryx”) (NASDAQ: CCXI) breached their fiduciary duties to ChemoCentryx and its shareholders. If you are a ChemoCentryx shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or jpettigrew@scott-scott.com.

These names are benefitting from M&A, clinical data and promising regulatory actions.